NEW ROCHELLE, N.Y.--(BUSINESS WIRE)--Biotech and pharmaceutical firms are becoming increasingly worried over the issue of counterfeit drugs, reports Genetic Engineering News (GEN) (www.genengnews.com). Their concerns are being fueled by higher threat levels, the value of the products involved, and the number of counterfeit drugs being produced, according to an article in the November 1 issue of GEN.
